What the global atmosphere is witnessing is the escalation of the new monkey epidemic, and also the raising of drug prices in Egypt by a decision of the Egyptian Medicine Authority. Entering the diverse winter season can be more difficult than summer is a paradise for Egyptian pharmaceutical companies listed on the Egyptian Stock Exchange From my personal...
Rapid change with almost certain assistance from its parent company What happened during the past period is like a miracle. The company transformed after the first quarter results showed huge losses and embezzlement charges that resulted in restructuring. After the distribution of closed dividends per share was suspended at 0.75 until liquidity was available, and...
Please note: I'm just sharing my view. its not a recommendation for buying or selling.
Looks like Biocept BIOC is making another technical move on more information from the company's website about its COVID testing. Apparently people on social are talking about updates that the company is doing COVID testing now. Company site specifically stating: "To support public health efforts, Biocept is performing COVID-19 testing. If you’re in need of...
BIOCEPT looks like it has silently broken out of its long term resistance... I'd venture a gamble to go long here. This could be a multi bagger if it works out.
NASDAQ:BIOC NASDAQ:BIOC Double bottom detected circa $0.26, potential for breakout to $0.45 to $0.48 for swing trade, then after that, resistance not until $0.68. Fundamental/news analysis is recommended as this is a medical laboratory and research company with a current price/book of 0.98. Risk/reward is high.
Surprised by another cash raise by BIOC. After the opening price crash again, and subsequent rise to the low $0.50's, had to take some risk off. Holding a smaller position and may accumulate if price action warrants it. If the company is going to use these funds to expand their burgeoning commercial operations this could be great for future growth. However...
Price and volume spike made this one show up on the screener. Seems like company has some things going on positive and negative, check out biocept.com. Decided on the rise, and subsequent pull-back to take a small risk on BIOC in the portfolio.
COMMENTARY BIOC is one of those penny stocks that have individual, good days. But when it comes to putting together a string of bullish action, it has yet to reach that milestone. Furthermore, though volume is good, the company still needs to execute further in my opinion. Either way. It's a good day today but would like to put this on a 30 day time clock and...
Biocept has the best-in-breed liquid biopsy testing in the Immuno-Oncology space. Market cap is 70 million, but it's going to be several billion in a few years if they don't get bought out first. Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of...
Blood diagnostic OncoCEE-BR was used by Columbia University College of Physicians and Surgeons in New York City to aid cancer patients' diagnosis. Involved biopsies are no longer required, cancer can be detected with a simple blood test. The chart has strong bullish divergence, has just made a breakout with an initial target around 4 dollars.